Dimethylarginine dimethylaminohydrolase: A new therapeutic target for the modulation of nitric oxide and angiogenesis

J. P. Singh

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Nitric oxide (NO) has a key role in promoting angiogenesis by increasing vasodilation, vascular permeability, endothelial cell proliferation and migration, and by modifying the activities of angiogenic mediators. NO is also critical for the mobilization of endothelial progenitor cells from the bone marrow which promotes vasculogenesis and angiogenesis. Studies have shown that the enzymes catalyzing NO synthesis are inhibited by the endogenously generated inhibitor asymmetric dimethylarginine (ADMA). Pharmacological agents targeted to modulate dimethyl-arginine dimethylaminohydrolase, the key enzyme metabolizing ADMA, may offer a potential strategy for developing novel pro- and anti-angiogenic therapies.

Original languageEnglish (US)
Pages (from-to)736-741
Number of pages6
JournalCurrent Opinion in Investigational Drugs
Volume8
Issue number9
StatePublished - Sep 2007
Externally publishedYes

Fingerprint

Nitric Oxide
Capillary Permeability
Enzymes
Vasodilation
Cell Movement
Arginine
Therapeutics
Endothelial Cells
Bone Marrow
Cell Proliferation
Pharmacology
dimethylargininase
N,N-dimethylarginine
Endothelial Progenitor Cells

Keywords

  • Angiogenesis
  • Asymmetric dimethylarginine
  • Dimethylarginine dimethylaminohydrolase
  • Nitric oxide
  • Progenitor cell

ASJC Scopus subject areas

  • Pharmacology

Cite this

Dimethylarginine dimethylaminohydrolase : A new therapeutic target for the modulation of nitric oxide and angiogenesis. / Singh, J. P.

In: Current Opinion in Investigational Drugs, Vol. 8, No. 9, 09.2007, p. 736-741.

Research output: Contribution to journalReview article

@article{93a0b54afef949799fb5eaab2695634d,
title = "Dimethylarginine dimethylaminohydrolase: A new therapeutic target for the modulation of nitric oxide and angiogenesis",
abstract = "Nitric oxide (NO) has a key role in promoting angiogenesis by increasing vasodilation, vascular permeability, endothelial cell proliferation and migration, and by modifying the activities of angiogenic mediators. NO is also critical for the mobilization of endothelial progenitor cells from the bone marrow which promotes vasculogenesis and angiogenesis. Studies have shown that the enzymes catalyzing NO synthesis are inhibited by the endogenously generated inhibitor asymmetric dimethylarginine (ADMA). Pharmacological agents targeted to modulate dimethyl-arginine dimethylaminohydrolase, the key enzyme metabolizing ADMA, may offer a potential strategy for developing novel pro- and anti-angiogenic therapies.",
keywords = "Angiogenesis, Asymmetric dimethylarginine, Dimethylarginine dimethylaminohydrolase, Nitric oxide, Progenitor cell",
author = "Singh, {J. P.}",
year = "2007",
month = "9",
language = "English (US)",
volume = "8",
pages = "736--741",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Dimethylarginine dimethylaminohydrolase

T2 - A new therapeutic target for the modulation of nitric oxide and angiogenesis

AU - Singh, J. P.

PY - 2007/9

Y1 - 2007/9

N2 - Nitric oxide (NO) has a key role in promoting angiogenesis by increasing vasodilation, vascular permeability, endothelial cell proliferation and migration, and by modifying the activities of angiogenic mediators. NO is also critical for the mobilization of endothelial progenitor cells from the bone marrow which promotes vasculogenesis and angiogenesis. Studies have shown that the enzymes catalyzing NO synthesis are inhibited by the endogenously generated inhibitor asymmetric dimethylarginine (ADMA). Pharmacological agents targeted to modulate dimethyl-arginine dimethylaminohydrolase, the key enzyme metabolizing ADMA, may offer a potential strategy for developing novel pro- and anti-angiogenic therapies.

AB - Nitric oxide (NO) has a key role in promoting angiogenesis by increasing vasodilation, vascular permeability, endothelial cell proliferation and migration, and by modifying the activities of angiogenic mediators. NO is also critical for the mobilization of endothelial progenitor cells from the bone marrow which promotes vasculogenesis and angiogenesis. Studies have shown that the enzymes catalyzing NO synthesis are inhibited by the endogenously generated inhibitor asymmetric dimethylarginine (ADMA). Pharmacological agents targeted to modulate dimethyl-arginine dimethylaminohydrolase, the key enzyme metabolizing ADMA, may offer a potential strategy for developing novel pro- and anti-angiogenic therapies.

KW - Angiogenesis

KW - Asymmetric dimethylarginine

KW - Dimethylarginine dimethylaminohydrolase

KW - Nitric oxide

KW - Progenitor cell

UR - http://www.scopus.com/inward/record.url?scp=34548310379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548310379&partnerID=8YFLogxK

M3 - Review article

C2 - 17729185

AN - SCOPUS:34548310379

VL - 8

SP - 736

EP - 741

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 9

ER -